Study of Causes of Death in Patients with Myelodysplastic Syndrome: A Single Institution Experience
| Autor: | Francesc Bosch, Olga Salamero, Esther Sancho, Noelia Valdez, Sabela Bobillo, Teresa Vallespi, Julia Montoro, David Valcárcel, M. Navarrete, Margarita Ortega, Carmen Sánchez-Morata, Laura Lopez-Andreoni |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cytopenia
medicine.medical_specialty Pediatrics business.industry Myelodysplastic syndromes Immunology Myeloid leukemia Cell Biology Hematology medicine.disease Biochemistry International Prognostic Scoring System hemic and lymphatic diseases Heart failure Internal medicine medicine In patient Single institution business Cause of death |
| Zdroj: | Blood. 118:5026-5026 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Abstract 5026 Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cell with low life expectancy due to several blood cytopenias and high risk of acute myeloid leukemia transformation (AML). Classically, evolution to AML, infection, and hemorrhage are reported as the main causes of death. However, there are few reports analyzing other causes of death in MDS patients, particularly the prevalence of non-MDS-related causes in large series from single-centers. We present here the analysis of causes of death of 200 patients (median age 75yr, range 16–96, 59% male) diagnosed of MDS in our institution between 2000 and 2010. Patients were diagnosed and classified according to the FAB criteria, WHO 2008 classification, IPSS (International Prognostic Scoring System) and SPI (Spanish Prognostic Index). Overall survival (OS) and survival of different MDS subtypes were analyzed. Two prognostic subgroups were defined: low-risk subgroup, composed by patients with low or intermediate-1 IPSS and low SPI; and high-risk subgroup, that included patients with intermediate-2 and high IPSS and intermediate and high SPI. Infection, hemorrhage, disease progression and transformation to AML were considered MDS-related deaths. All other causes of death were classified as non-MDS-related. Median follow-up of the series was 1.8 years (range: 0–11 years). MDS subtypes distribution was as follows: RA, RARS and 5q– 19%; RCMD and RCMD-RS 32%; RAEB-1 and RAEB-2 27%; hypoplastic and unclassified MDS 8%; and CMML 13%. One hundred twenty-nine patients (64.5%) belonged to the low-risk subgroup, whereas 65 patients (32.5%) to the high-risk subgroup. Only 6 patients (3%) could not be classified. Median OS of the whole series was 2 years, being of 3.7 years in the low-risk subgroup and of 0.9 years in the high-risk subgroup (P Disclosures: No relevant conflicts of interest to declare. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|